Overview of Credit and Guarantee Situation - The company has approved a comprehensive credit application not exceeding 200 million yuan, with a guarantee of 100 million yuan for its subsidiary, Shenyang Junyuan Pharmaceutical Co., Ltd. [1] - The board of directors approved this decision to support the operational and future development needs of the company and its subsidiary [1]. Progress of Guarantee - The subsidiary Junyuan Pharmaceutical has applied for a financing loan from China Everbright Bank Luxembourg Branch, and the company has signed a contract with Hangzhou Bank Beijing Branch for a guarantee [2]. - The company applied for a comprehensive credit limit of 100 million yuan from Hangzhou Bank, utilizing 21.09989 million yuan for a financing guarantee, benefiting Everbright Bank Luxembourg Branch [2]. Main Contents of Guarantee Contract and Loan Agreement - The guarantee amount for the external guarantee/standby letter of credit contract is USD 2.95 million, with a guarantee expiration date of June 18, 2026 [2][3]. - The loan agreement specifies that the borrower is Shenyang Junyuan Pharmaceutical Co., Ltd., with a loan amount of USD 2.8 million for daily operational needs [3]. Cumulative External Guarantee Situation - As of the announcement date, the total approved external guarantee amount is 21.09989 million yuan, accounting for 0.61% of the company's latest audited net assets [3]. - The company has no overdue guarantees and does not provide guarantees for non-affiliated parties or those involved in litigation [3].

证券代码:300485 证券简称：赛升药业 公告编号：2025-027 北京赛升药业股份有限公司 关于公司向金融机构申请综合授信并 为子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 一、授信及担保情况概述 北京赛升药业股份有限公司（以下简称"公司"）于 2025 年 3 月 27 日召开了 第五届董事会第六次会议及第五届监事会第六次会议，审议通过了《关于公司向金 融机构申请综合授信并为子公司提供担保的议案》，为满足公司及子公司沈阳君元 药业有限公司（以下简称"君元药业"或"子公司"）生产经营和未来发展需要， 公司董事会同意公司向金融机构申请不超过 20,000 万元的综合授信额度，其中公 司拟为君元药业向银行申请 10,000 万授信提供连带责任保证担保。具体内容详见 公司于 2025 年 3 月 29 日在巨潮资讯网（www.cninfo.com.cn）披露的《关于公司 向金融机构申请综合授信并为子公司提供担保的公告》（公告编号：2025-014）。 二、担保进展情况 鉴于子公司君元药业向中国光大银行股份有限公司卢森堡分行申请融资贷 ...

企业名称：沈阳君元药业有限公司 注册地址：沈阳市浑南区麦子屯 603 号沈阳浑南生物医药产业园 9 号楼 证券代码：300485 证券简称：赛升药业 公告编号：2025-026 北京赛升药业股份有限公司 关于子公司药品生产许可证变更的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 北京赛升药业股份有限公司（以下简称"公司"）子公司沈阳君元药业有限 公司（以下简称"君元药业"）近日获得了辽宁省药品监督管理局颁发的《药品 生产许可证》。本次涉及变更的事项为：同意该企业将已上市药品杏仁止咳颗粒 （国药准字 Z21020722）的生产场地由沈阳市浑南新区（暨沈阳国家高新技术产 业开发区）古城子甲-66 号变更为沈阳市浑南区麦子屯 603 号 9 号楼，22 号楼， 其他内容不变。 现将相关信息公告如下： 一、《药品生产许可证》的基本信息 生产地址和生产范围：沈阳市浑南区麦子屯 603 号 9 号楼，22 号楼：片剂、 颗粒剂、硬胶囊剂、丸剂（水丸）、溶液剂（外用、含激素类）、酊剂（外用、 含激素类）、搽剂、栓剂、小容量注射剂*** 二、对公司的影响 本次《药品生 ...

Group 1 - The innovative drug sector is experiencing a resurgence, with significant stock price increases for companies such as Chengda Pharmaceutical (+14.05%) and Huisheng Pharmaceutical (+9.45%) [1][2] - The National Healthcare Security Administration (NHSA) is actively promoting high-quality development of innovative drugs through a series of meetings and discussions with industry representatives [3] - The NHSA's commitment to supporting genuine innovation and establishing a comprehensive value evaluation system for innovative drugs is expected to enhance the efficient use of healthcare resources [3] Group 2 - CITIC Securities reports that the NHSA's ongoing efforts in centralized procurement and negotiation will shift the market focus from low-price competition to quality and cost control, benefiting companies with strong quality systems and cost advantages [4] - The innovative drug sector is anticipated to receive continued policy support, with commercial insurance policies providing additional growth opportunities [4] - By 2025, the domestic innovative drug industry is expected to reach a turning point, transitioning from capital-driven to profit-driven growth, presenting dual opportunities for performance and valuation recovery [4]

Group 1 - The recombinant protein concept sector rose by 2.85%, ranking fifth among concept sectors, with 46 stocks increasing in value [1] - Notable gainers included Shenzhou Cell and Weiming Pharmaceutical, both reaching the daily limit, while Saiseng Pharmaceutical, Hotgen Biotech, and Huiyu Pharmaceutical also saw significant increases of 10.45%, 10.38%, and 8.43% respectively [1] - The sector experienced a net inflow of 568 million yuan, with 30 stocks receiving net inflows, and five stocks attracting over 30 million yuan each [2] Group 2 - Leading the net inflow was Weiming Pharmaceutical, which saw a net inflow of 89.46 million yuan, followed by Kexing Pharmaceutical, Yipin Hong, and Huiyu Pharmaceutical with net inflows of 74.06 million yuan, 71.16 million yuan, and 60.03 million yuan respectively [2][3] - The net inflow ratios for Weiming Pharmaceutical, Kexing Pharmaceutical, and Huiyu Pharmaceutical were 24.18%, 13.33%, and 12.60% respectively [3] - The overall performance of the recombinant protein sector was supported by strong trading activity, with several stocks showing high turnover rates [3][4]

Investment Rating - The report maintains a "Recommended" investment rating for the healthcare sector [7]. Core Insights - The healthcare sector has shown a mixed performance, with the Shenyin Wanguo Pharmaceutical Bio Index rising by 1.60% from June 23 to June 27, 2025, underperforming the CSI 300 Index by 0.35 percentage points [2][12]. - Year-to-date, the pharmaceutical sector has increased by 6.24%, outperforming the CSI 300 Index by 6.57 percentage points, ranking 11th among 31 sectors [2][14]. - As of June 27, 2025, the valuation of the pharmaceutical sector stands at 27.54 times (TTM overall method, excluding negative values), with a premium of 140.94% compared to the CSI 300 [2][17]. Summary by Sections 1. Market Performance - The pharmaceutical sector's performance from June 23 to June 27, 2025, was a 1.60% increase, ranking 23rd among 31 sectors [12]. - The year-to-date performance shows a 6.24% increase, ranking 11th among 31 sectors [14]. 2. Important Events - The National Healthcare Security Administration released the "2025 Basic Medical Insurance Directory and Commercial Insurance Innovative Drug Directory Adjustment Application Guidelines," marking a significant step for commercial health insurance in the multi-level medical security system [4][21]. 3. Industry Perspective - The inclusion of the commercial insurance innovative drug directory indicates an enhanced role for commercial insurance in the multi-level medical security system, providing greater opportunities for the industry [5][22]. - The report expresses optimism for innovative drugs, overseas expansion, and the clearing of procurement in specific segments, suggesting a focus on companies involved in these areas [22].

Group 1 - The innovative drug concept is experiencing a volatile rebound, with Sai Sheng Pharmaceutical (300485) hitting a 20% limit up, while companies like Anglikang (002940), Watson Bio (300142), Yuekang Pharmaceutical, Saint Nuo Bio, and Rongchang Bio also saw significant gains [1] - There is a disclosure of dark pool fund flows, indicating early signals of stock accumulation by major investors [1]

Group 1 - Shengnuo Bio expects a net profit attributable to shareholders of 77.03 million to 94.14 million yuan for the first half of 2025, representing a year-on-year increase of 253.54% to 332.10% [1] - The significant growth in Shengnuo Bio's performance is primarily attributed to the strong performance of its peptide raw material business, which is closely related to GLP-1 formulations [1] Group 2 - Shanghai Laishi has completed the acquisition of 100% equity in Nanyue Bio for 4.2 billion yuan, with an additional contingent payment of 50 million yuan if the company processes 305 tons of plasma by 2025 [2] - The completion of the acquisition and registration marks a significant step forward in Shanghai Laishi's "plasma expansion" strategy, although it is expected to add substantial goodwill, raising concerns about future impairment risks [2] Group 3 - Beijing Saisheng Pharmaceutical has signed a new drug technology transfer agreement with its affiliate, transferring technology related to the NeoAB33 new drug project for a total of 20 million yuan [3] - The transfer may optimize the asset structure of Huada Protein, which reported a loss of 8.3 million yuan in 2024, while Saisheng Pharmaceutical reported a net profit of 39.97 million yuan in the first quarter of 2025, indicating its financial capability to advance research and development [3] Group 4 - Eli Lilly's reversible BTK inhibitor, Pirtobrutinib, has had its new indication application accepted for review in China, targeting patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who have previously received BTK inhibitor treatment [4] - If approved, Pirtobrutinib will provide a new treatment option for patients who have failed previous covalent BTK inhibitor therapies, further solidifying its market position in the treatment of B-cell malignancies [4] Group 5 - Innovent Biologics' CLDN-18.2 ADC product, IBI343, is proposed to be included as a breakthrough therapy for locally advanced or metastatic pancreatic cancer expressing CLDN 18.2, after at least two systemic treatments [5] - As the first CLDN18.2 ADC to achieve a breakthrough in pancreatic cancer, IBI343 is expected to fill a gap in second-line and later treatments, providing new options for patients [5]

Core Viewpoint - Multiple companies have announced significant developments, including investments, clarifications on business operations, and changes in control, which may present various investment opportunities and risks for stakeholders [2]. Company Announcements - **Hai Zheng Pharmaceutical** plans to establish a joint venture in synthetic biology with a registered capital of 350 million yuan, where Hai Zheng will contribute 260 million yuan, holding a 74.29% stake [3]. - **Jin Zhong Zi Jiu** clarified that its business scope remains unchanged despite media reports suggesting a shift away from liquor production, confirming that it will continue to focus on its core liquor business [4]. - **ST Gong Zhi** announced that its stock will resume trading on June 20, 2025, and enter a delisting period, with the last trading date expected to be July 10, 2025 [5]. - **Zhong Jing Electronics** confirmed that its production and operational conditions are normal, with no undisclosed significant matters [6]. - **Shan Jin International** is preparing for an overseas H-share issuance and listing on the Hong Kong Stock Exchange to enhance its global strategy [7]. - **Kang Da New Materials** intends to acquire at least 51% of Chengdu Zhongke Huamei Electronics to expand into the semiconductor integrated circuit sector [8]. - **Zhong Yan Chemical** agreed to a capital reduction for its subsidiary, which will result in it holding 100% of the subsidiary's equity, constituting a significant asset restructuring [9]. - **Tai Ji Co., Ltd.** announced a change in its actual controller to the Hubei Provincial State-owned Assets Supervision and Administration Commission, with stock resuming trading [10]. - **ST Yi Guo** plans to sell four Carrefour subsidiaries for 1 yuan, expecting to increase its net profit by approximately 572 million yuan, while focusing on its core home appliance business [11][12]. Performance Expectations - **Sheng Nuo Bio** anticipates a substantial increase in net profit for the first half of 2025, projecting a year-on-year growth of 253.54% to 332.10%, driven by strong performance in its peptide raw material business [13]. Share Buyback - **Nuo Wei Zan** intends to repurchase shares worth between 5 million and 10 million yuan to implement employee stock ownership plans, with a maximum repurchase price of 30 yuan per share [14]. Major Contracts - **Sai Sheng Pharmaceutical** signed a technology transfer contract for a new drug project with a total transaction amount of 20 million yuan, which will enhance its capabilities in the protein/antibody drug platform [15].

Meeting Details - The fifth meeting of the Supervisory Board of Beijing Saiseng Pharmaceutical Co., Ltd. was held on June 19, 2025, with all three attending supervisors present [1][2] - The meeting was legally convened in accordance with relevant laws and regulations [1] Resolutions Passed - The Supervisory Board approved the proposal regarding the signing of a "New Drug Technology Transfer Contract" and related transactions [1][2] - The board confirmed that the transaction is necessary for the company's normal operations and aligns with its development strategy [2] Compliance and Impact - The Supervisory Board concluded that the transaction complies with legal and regulatory requirements and does not affect the company's independence or harm the interests of shareholders, particularly minority shareholders [2]